Show results for
Refine by
Post Traumatic Stress Disorder System Ptsd Suppliers Serving Namibia
5 companies found
based inBerwyn, PENNSYLVANIA (USA)
Virpax Pharmaceuticals specializes in developing novel and proprietary drug-delivery systems across various pain and CNS disorder indications to enhance compliance and to optimize the efficacy of each product candidate. Our transforming ...
based inMountain View, CALIFORNIA (USA)
At Inscopix, we seek to unlock human potential by developing advanced technologies and quantitative neural circuit-based approaches to understand the brain in health and to heal it in disease. Positioned at the intersection of neuroscience, ...
based inCambridge, UNITED KINGDOM
GW is the global leader in developing cannabinoid-based medicines. GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics. GW has established a world ...
Our proprietary complex botanical mixture, called nabiximols (Sativex® outside of the U.S.) is an oromucosal spray of a formulated cannabis extract that contains the principal cannabinoids delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD) ...
based inMississauga, ONTARIO (CANADA)
Award-winning, Clinical Stage/Life-Sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The company is targeting anxiety, depression, ...
Mentanine®, supported by (cannabidiol “CBD” + IP formula) – molecules bond and synergistically attach to PPAR receptors allowing the formula to cross the blood-brain barrier (BBB) to target the central nervous ...
based inChatham, NEW JERSEY (USA)
Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. At Tonix, we are focused on ...
TNX-102 SL is a small, rapidly-disintegrating, under the tongue (sublingual) product candidate containing 2.8 mg of cyclobenzaprine HCl. The unique patented formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for ...